ES2723098T3 - Agonistas del péptido CRHR2 y usos de los mismos - Google Patents
Agonistas del péptido CRHR2 y usos de los mismos Download PDFInfo
- Publication number
- ES2723098T3 ES2723098T3 ES09748922T ES09748922T ES2723098T3 ES 2723098 T3 ES2723098 T3 ES 2723098T3 ES 09748922 T ES09748922 T ES 09748922T ES 09748922 T ES09748922 T ES 09748922T ES 2723098 T3 ES2723098 T3 ES 2723098T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide agonists
- peptide
- crhr2 peptide
- crhr2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
Un péptido que tiene actividad agonista hacia el receptor de la hormona liberadora de corticotropina tipo 2, dicho péptido tiene una secuencia de aminoácidos seleccionada del grupo que consiste de las SEQ ID NO 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, 39 , 40, y 41; o una sal o amida farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11123308P | 2008-11-04 | 2008-11-04 | |
US17889009P | 2009-05-15 | 2009-05-15 | |
PCT/US2009/063276 WO2010053990A2 (en) | 2008-11-04 | 2009-11-04 | Crhr2 peptide agonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2723098T3 true ES2723098T3 (es) | 2019-08-21 |
Family
ID=41509080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09748922T Active ES2723098T3 (es) | 2008-11-04 | 2009-11-04 | Agonistas del péptido CRHR2 y usos de los mismos |
Country Status (20)
Country | Link |
---|---|
US (1) | US10040838B2 (es) |
EP (1) | EP2362881B1 (es) |
JP (1) | JP2012508014A (es) |
KR (1) | KR20110091720A (es) |
CN (1) | CN102272151B (es) |
AU (1) | AU2009313619A1 (es) |
BR (1) | BRPI0921640A2 (es) |
CA (1) | CA2742710A1 (es) |
CO (1) | CO6341479A2 (es) |
CR (1) | CR20110305A (es) |
EA (1) | EA201170647A1 (es) |
EC (1) | ECSP11011099A (es) |
ES (1) | ES2723098T3 (es) |
IL (1) | IL212685A0 (es) |
MX (1) | MX2011004718A (es) |
NI (1) | NI201100087A (es) |
NZ (1) | NZ592670A (es) |
SG (1) | SG171957A1 (es) |
WO (1) | WO2010053990A2 (es) |
ZA (1) | ZA201104160B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009313619A1 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
AU2010315131A1 (en) * | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
HUE036640T2 (hu) * | 2012-02-14 | 2018-07-30 | Univ California | Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra |
JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0452484T3 (da) | 1989-11-06 | 1996-10-14 | Cell Genesys Inc | Fremstilling af proteiner ved homolog rekombination |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
CA2288429C (en) * | 1991-03-15 | 2006-04-25 | Synergen, Inc. | Pegylation of polypeptides |
US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US6812210B2 (en) * | 2001-03-15 | 2004-11-02 | Research Development Foundation | Urocortin-III and uses thereof |
CN1236831C (zh) | 2001-05-21 | 2006-01-18 | 茵捷特数码浮质有限公司 | 用于经肺部途径递送蛋白质的组合物 |
AU2002351214B2 (en) * | 2001-12-03 | 2008-09-11 | Metabolex, Inc. | Methods and reagents for diagnosis and treatment of diabetes |
CN100480267C (zh) * | 2002-01-16 | 2009-04-22 | 宝洁公司 | 促肾上腺皮质激素释放因子2受体激动剂 |
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
KR100512483B1 (ko) * | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
EP2322569B1 (en) * | 2003-10-09 | 2020-08-26 | Ambrx, Inc. | Polymer derivatives for the selective modification of proteins |
US20080261863A1 (en) * | 2004-06-12 | 2008-10-23 | Bayer Pharmaceuticals Corp | Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use |
PA8660701A1 (es) * | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
EP2164522A2 (en) | 2007-05-25 | 2010-03-24 | Neutron Ltd. | Crf conjugates with extended half-lives |
RU2010114038A (ru) | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза |
EP2205748A1 (en) | 2007-09-14 | 2010-07-14 | BASF Plant Science GmbH | Plants having increased yield-related traits and a method for making the same |
AU2009313619A1 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
JP2013506697A (ja) | 2009-10-06 | 2013-02-28 | アンジオケム インコーポレーテッド | 治療薬を輸送するための組成物と方法 |
AU2010315131A1 (en) * | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
AU2012284122B2 (en) | 2011-07-18 | 2017-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting polyomavirus-associated pathology |
-
2009
- 2009-11-04 AU AU2009313619A patent/AU2009313619A1/en not_active Abandoned
- 2009-11-04 WO PCT/US2009/063276 patent/WO2010053990A2/en active Application Filing
- 2009-11-04 KR KR1020117012435A patent/KR20110091720A/ko not_active Application Discontinuation
- 2009-11-04 NZ NZ592670A patent/NZ592670A/xx not_active IP Right Cessation
- 2009-11-04 MX MX2011004718A patent/MX2011004718A/es not_active Application Discontinuation
- 2009-11-04 BR BRPI0921640A patent/BRPI0921640A2/pt not_active IP Right Cessation
- 2009-11-04 ES ES09748922T patent/ES2723098T3/es active Active
- 2009-11-04 CN CN200980154228.3A patent/CN102272151B/zh not_active Expired - Fee Related
- 2009-11-04 EA EA201170647A patent/EA201170647A1/ru unknown
- 2009-11-04 CA CA2742710A patent/CA2742710A1/en not_active Abandoned
- 2009-11-04 JP JP2011535643A patent/JP2012508014A/ja active Pending
- 2009-11-04 US US12/612,548 patent/US10040838B2/en active Active
- 2009-11-04 SG SG2011040755A patent/SG171957A1/en unknown
- 2009-11-04 EP EP09748922.3A patent/EP2362881B1/en active Active
-
2011
- 2011-05-04 IL IL212685A patent/IL212685A0/en unknown
- 2011-05-04 NI NI201100087A patent/NI201100087A/es unknown
- 2011-05-18 CO CO11061124A patent/CO6341479A2/es active IP Right Grant
- 2011-06-02 EC EC2011011099A patent/ECSP11011099A/es unknown
- 2011-06-03 ZA ZA2011/04160A patent/ZA201104160B/en unknown
- 2011-06-06 CR CR20110305A patent/CR20110305A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2011004718A (es) | 2011-07-28 |
ZA201104160B (en) | 2012-11-28 |
NZ592670A (en) | 2013-01-25 |
WO2010053990A3 (en) | 2010-07-01 |
CN102272151A (zh) | 2011-12-07 |
CA2742710A1 (en) | 2010-05-14 |
IL212685A0 (en) | 2011-07-31 |
WO2010053990A2 (en) | 2010-05-14 |
SG171957A1 (en) | 2011-07-28 |
EA201170647A1 (ru) | 2011-12-30 |
ECSP11011099A (es) | 2011-07-29 |
EP2362881A2 (en) | 2011-09-07 |
AU2009313619A1 (en) | 2010-05-14 |
BRPI0921640A2 (pt) | 2019-09-24 |
JP2012508014A (ja) | 2012-04-05 |
US20100130424A1 (en) | 2010-05-27 |
CO6341479A2 (es) | 2011-11-21 |
US10040838B2 (en) | 2018-08-07 |
CN102272151B (zh) | 2014-08-20 |
CR20110305A (es) | 2011-11-10 |
EP2362881B1 (en) | 2019-03-13 |
KR20110091720A (ko) | 2011-08-12 |
NI201100087A (es) | 2011-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2619322T3 (es) | Agente inductor de inmunidad | |
HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
ES2526292T3 (es) | Antagonistas de la somatostatina selectivos para receptor (SSTR2) | |
ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
PE20100255A1 (es) | Co-agonistas del receptor de glucagon/glp-1 | |
ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
ES2536974T3 (es) | Péptidos de epítopos del receptor de EGF y usos de los mismos | |
ES2723098T3 (es) | Agonistas del péptido CRHR2 y usos de los mismos | |
CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
AR108277A2 (es) | Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas | |
ES2721172T3 (es) | Una nueva clase de moléculas terapéuticas a base de proteínas | |
AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
PE20070521A1 (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a | |
CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
HRP20090245T1 (en) | Pyy agonists and uses thereof | |
ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
PE20142114A1 (es) | Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos | |
BR112015030326A2 (pt) | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos | |
AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
PE20121528A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
CO6260099A2 (es) | Depsipeptidos ciclicos |